Literature DB >> 7783874

Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects.

P J Dyck1, W J Litchy, K A Lehman, J L Hokanson, P A Low, P C O'Brien.   

Abstract

We determined the normal limits for various neuropathic tests in healthy subjects. The study, the Rochester Diabetic Neuropathy Study (RDNS), is noteworthy because of its size (more than 400 subjects), random selection of subjects, and selection of at least 15 men and 15 women without neuropathy, neurologic disease, or diseases predisposing to neuropathy from each hemidecade between 18 and 74 years of age from the population of a defined region (Rochester, MN). Subjects were classified into those with (nonhealthy subjects, RDNS-NS) and without (healthy subjects, RDNS-HS) neuropathy, neurologic or psychiatric disease, or diseases known to predispose to neuropathy. The study provides normal limits for tests used in the RDNS but it has broader uses as well. We found that (1) less than 10% of subjects in the third decade, approximately 20% in the fourth decade, and approximately 30% in the fifth or older decades were placed into the RDNS-NS category; (2) healthy subjects (RDNS-HS) retain their ability to walk on toes and heels regardless of age, excessive weight, or lack of physical fitness, but not their ability to arise from a kneeled position--lost in more than 5% of persons 60 years and older; (3) the frequency of decreased or absent ankle reflexes exceeds 5% in healthy subjects older than 50 years--limiting their value as a sign of diabetic polyneuropathy and necessitating a grading change with age in the neuropathy impairment score.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7783874     DOI: 10.1212/wnl.45.6.1115

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  63 in total

1.  Therapeutic strategies for the inherited neuropathies.

Authors:  Michael E Shy
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

2.  The meaning of distal sensory loss and absent ankle reflexes in relation to age: a meta-analysis.

Authors:  Alexander F J E Vrancken; Sandra Kalmijn; Frans Brugman; Gabriël J E Rinkel; Nicolette C Notermans
Journal:  J Neurol       Date:  2005-11-23       Impact factor: 4.849

3.  Multicenter trial of the proficiency of smart quantitative sensation tests.

Authors:  Peter J Dyck; Barbara Argyros; James W Russell; Linde E Gahnstrom; Susan Nalepa; James W Albers; Karen A Lodermeier; Andrew J Zafft; P James B Dyck; Christopher J Klein; William J Litchy; Jenny L Davies; Rickey E Carter; L Joseph Melton
Journal:  Muscle Nerve       Date:  2014-01-28       Impact factor: 3.217

Review 4.  Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.

Authors:  Peter J Dyck; Bruce V Taylor; Jenny L Davies; Michelle L Mauermann; William J Litchy; Christopher J Klein; P James B Dyck
Journal:  Muscle Nerve       Date:  2015-08-13       Impact factor: 3.217

5.  Epidermal nerve fibers: confidence intervals and continuous measures with nerve conduction.

Authors:  JaNean K Engelstad; Sean W Taylor; Lawrence V Witt; Belinda J Hoebing; David N Herrmann; P James B Dyck; Christopher J Klein; David M Johnson; Jenny L Davies; Rickey E Carter; Peter J Dyck
Journal:  Neurology       Date:  2012-10-24       Impact factor: 9.910

6.  Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial.

Authors:  Peter J Dyck; John C Kincaid; P James B Dyck; Vinay Chaudhry; Namita A Goyal; Christina Alves; Hayet Salhi; Janice F Wiesman; Celine Labeyrie; Jessica Robinson-Papp; Márcio Cardoso; Matilde Laura; Katherine Ruzhansky; Andrea Cortese; Thomas H Brannagan; Julie Khoury; Sami Khella; Márcia Waddington-Cruz; João Ferreira; Annabel K Wang; Marcus V Pinto; Samar S Ayache; Merrill D Benson; John L Berk; Teresa Coelho; Michael Polydefkis; Peter Gorevic; David H Adams; Violaine Plante-Bordeneuve; Carol Whelan; Giampaolo Merlini; Stephen Heitner; Brian M Drachman; Isabel Conceição; Christopher J Klein; Morie A Gertz; Elizabeth J Ackermann; Steven G Hughes; Michelle L Mauermann; Rito Bergemann; Karen A Lodermeier; Jenny L Davies; Rickey E Carter; William J Litchy
Journal:  Muscle Nerve       Date:  2017-04-07       Impact factor: 3.217

7.  A controlled study of medial arterial calcification of legs: implications for diabetic polyneuropathy.

Authors:  Joon-Shik Moon; Vicki M Clark; John W Beabout; Ronald G Swee; Peter James Dyck
Journal:  Arch Neurol       Date:  2011-10

8.  Follow-up of advanced diabetic neuropathy: useful variables and possible pitfalls.

Authors:  H H Krämer; R Rolke; M Hecht; A Bickel; F Birklein
Journal:  J Neurol       Date:  2005-02-23       Impact factor: 4.849

Review 9.  Measurement of somatic neuropathy for clinical practice and clinical trials.

Authors:  L V Scott; S Tesfaye
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

10.  Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.

Authors:  John L Berk; Ole B Suhr; Laura Obici; Yoshiki Sekijima; Steven R Zeldenrust; Taro Yamashita; Michael A Heneghan; Peter D Gorevic; William J Litchy; Janice F Wiesman; Erik Nordh; Manuel Corato; Alessandro Lozza; Andrea Cortese; Jessica Robinson-Papp; Theodore Colton; Denis V Rybin; Alice B Bisbee; Yukio Ando; Shu-ichi Ikeda; David C Seldin; Giampaolo Merlini; Martha Skinner; Jeffery W Kelly; Peter J Dyck
Journal:  JAMA       Date:  2013-12-25       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.